Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 911

1.

Effects of concomitant inactivation of p53 and pRb on response to doxorubicin treatment in breast cancer cell lines.

Huun J, Lønning PE, Knappskog S.

Cell Death Discov. 2017 May 22;3:17026. doi: 10.1038/cddiscovery.2017.26. eCollection 2017.

2.

High-throughput validation of ceRNA regulatory networks.

Chiu HS, Martínez MR, Bansal M, Subramanian A, Golub TR, Yang X, Sumazin P, Califano A.

BMC Genomics. 2017 May 30;18(1):418. doi: 10.1186/s12864-017-3790-7.

3.

Functional interaction between co-expressed MAGE-A proteins.

Laiseca JE, Ladelfa MF, Cotignola J, Peche LY, Pascucci FA, Castaño BA, Galigniana MD, Schneider C, Monte M.

PLoS One. 2017 May 24;12(5):e0178370. doi: 10.1371/journal.pone.0178370. eCollection 2017.

4.

Tonic suppression of PCAT29 by the IL-6 signaling pathway in prostate cancer: Reversal by resveratrol.

Al Aameri RFH, Sheth S, Alanisi EMA, Borse V, Mukherjea D, Rybak LP, Ramkumar V.

PLoS One. 2017 May 3;12(5):e0177198. doi: 10.1371/journal.pone.0177198. eCollection 2017.

5.

Metabolic heterogeneity signature of primary treatment-naïve prostate cancer.

Lin D, Ettinger SL, Qu S, Xue H, Nabavi N, Choi SYC, Bell RH, Mo F, Haegert AM, Gout PW, Fleshner N, Gleave ME, Pollak M, Collins CC, Wang Y.

Oncotarget. 2017 Apr 18;8(16):25928-25941. doi: 10.18632/oncotarget.15237.

6.

A computational systems approach identifies synergistic specification genes that facilitate lineage conversion to prostate tissue.

Talos F, Mitrofanova A, Bergren SK, Califano A, Shen MM.

Nat Commun. 2017 Apr 21;8:14662. doi: 10.1038/ncomms14662.

7.

Next generation mapping reveals novel large genomic rearrangements in prostate cancer.

Jaratlerdsiri W, Chan EKF, Petersen DC, Yang C, Croucher PI, Bornman MSR, Sheth P, Hayes VM.

Oncotarget. 2017 Apr 4;8(14):23588-23602. doi: 10.18632/oncotarget.15802.

8.

AR Signaling and the PI3K Pathway in Prostate Cancer.

Crumbaker M, Khoja L, Joshua AM.

Cancers (Basel). 2017 Apr 15;9(4). pii: E34. doi: 10.3390/cancers9040034. Review.

9.

The combined effect of USP7 inhibitors and PARP inhibitors in hormone-sensitive and castration-resistant prostate cancer cells.

Morra F, Merolla F, Napolitano V, Ilardi G, Miro C, Paladino S, Staibano S, Cerrato A, Celetti A.

Oncotarget. 2017 May 9;8(19):31815-31829. doi: 10.18632/oncotarget.16463.

10.

Family with sequence similarity 13C (FAM13C) overexpression is an independent prognostic marker in prostate cancer.

Burdelski C, Borcherding L, Kluth M, Hube-Magg C, Melling N, Simon R, Möller-Koop C, Weigand P, Minner S, Haese A, Michl HU, Tsourlakis MC, Jacobsen F, Hinsch A, Wittmer C, Lebok P, Steurer S, Izbicki JR, Sauter G, Krech T, Büscheck F, Clauditz T, Schlomm T, Wilczak W.

Oncotarget. 2017 May 9;8(19):31494-31508. doi: 10.18632/oncotarget.16357.

11.

c-Myc Antagonises the Transcriptional Activity of the Androgen Receptor in Prostate Cancer Affecting Key Gene Networks.

Barfeld SJ, Urbanucci A, Itkonen HM, Fazli L, Hicks JL, Thiede B, Rennie PS, Yegnasubramanian S, DeMarzo AM, Mills IG.

EBioMedicine. 2017 Apr;18:83-93. doi: 10.1016/j.ebiom.2017.04.006. Epub 2017 Apr 5.

12.

Probing the prostate tumour microenvironment II: Impact of hypoxia on a cell model of prostate cancer progression.

Tonry C, Armstrong J, Pennington S.

Oncotarget. 2017 Feb 28;8(9):15307-15337. doi: 10.18632/oncotarget.14574.

13.

NUSAP1 promotes invasion and metastasis of prostate cancer.

Gordon CA, Gong X, Ganesh D, Brooks JD.

Oncotarget. 2017 May 2;8(18):29935-29950. doi: 10.18632/oncotarget.15604.

14.

Computational identification of mutually exclusive transcriptional drivers dysregulating metastatic microRNAs in prostate cancer.

Xue M, Liu H, Zhang L, Chang H, Liu Y, Du S, Yang Y, Wang P.

Nat Commun. 2017 Apr 11;8:14917. doi: 10.1038/ncomms14917.

15.

Database-augmented Mass Spectrometry Analysis of Exosomes Identifies Claudin 3 as a Putative Prostate Cancer Biomarker.

Worst TS, von Hardenberg J, Gross JC, Erben P, Schnölzer M, Hausser I, Bugert P, Michel MS, Boutros M.

Mol Cell Proteomics. 2017 Jun;16(6):998-1008. doi: 10.1074/mcp.M117.068577. Epub 2017 Apr 9.

PMID:
28396511
16.

Molecular classification of prostate adenocarcinoma by the integrated somatic mutation profiles and molecular network.

Yang L, Wang S, Zhou M, Chen X, Jiang W, Zuo Y, Lv Y.

Sci Rep. 2017 Apr 7;7(1):738. doi: 10.1038/s41598-017-00872-8.

17.

Role of Antigen Spread and Distinctive Characteristics of Immunotherapy in Cancer Treatment.

Gulley JL, Madan RA, Pachynski R, Mulders P, Sheikh NA, Trager J, Drake CG.

J Natl Cancer Inst. 2017 Apr 1;109(4). doi: 10.1093/jnci/djw261.

18.

Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer.

Ho Y, Dehm SM.

Endocrinology. 2017 Jun 1;158(6):1533-1542. doi: 10.1210/en.2017-00109.

PMID:
28368512
19.

Role of steroid receptor and coregulator mutations in hormone-dependent cancers.

Groner AC, Brown M.

J Clin Invest. 2017 Apr 3;127(4):1126-1135. doi: 10.1172/JCI88885. Epub 2017 Apr 3.

20.

Emerging Variants of Castration-Resistant Prostate Cancer.

Vlachostergios PJ, Puca L, Beltran H.

Curr Oncol Rep. 2017 May;19(5):32. doi: 10.1007/s11912-017-0593-6. Review.

PMID:
28361223

Supplemental Content

Support Center